Tyk2 deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice

International Immunology

Volumn 23, Issue 9, 2011, Pages 575-582

  Ishizaki, Masayuki ^a,b   Muromoto, Ryuta ^a   Akimoto, Toshihiko ^b   Ohshiro, Yuya ^a   Takahashi, Miki ^a   Sekine, Yuichi ^a   Maeda, Hiroaki ^b   Shimoda, Kazuya ^c   Oritani, Kenji ^d   Matsuda, Tadashi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b DAIICHI SANKYO CO   (Japan)

^c UNIVERSITY OF MIYAZAKI   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti type II collagen antibody induced arthritis; Rheumatoid arthritis; Tyk2

Indexed keywords

COLLAGEN ANTIBODY; COLLAGEN TYPE 2; COLLAGEN TYPE 2 ANTIBODY; CYTOKINE; MATRIX METALLOPROTEINASE; PROTEIN KINASE TYK2; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ARTHRITIS; ARTICLE; ARTICULAR CARTILAGE; CELL INFILTRATION; COLLAGEN ANTIBODY INDUCED ARTHRITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; ERYTHEMA; FOREFOOT; HINDLIMB; HISTOPATHOLOGY; IMMUNIZATION; IN VIVO STUDY; INFLAMMATORY CELL; INJECTION; JOINT DESTRUCTION; JOINT SWELLING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RHEUMATOID ARTHRITIS; TH1 CELL; TH17 CELL; WILD TYPE;

EID: 80051865705     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxr057     Document Type: Article

References (40)

1. Boers, M. 2001. Rheumatoid arthritis. Treatment of early disease. Rheum. Dis. Clin. North Am. 27:405.
2. Gay, S. 2001. Rheumatoid arthritis. Curr. Opin. Rheumatol. 13:191.
3. Schett, G., Tohidast-Akrad, M., Steiner, G. and Smolen, J. 2001. The stressed synovium. Arthritis Res. 3:80.
4. Stastny, P., Ball, E. J., Dry, P. J. and Nunez, G. 1983. The human immune response region (HLA-D) and disease susceptibility. Immunol. Rev. 70:113.
5. Quayle, A. J., Chomarat, P., Miossec, P., Kjeldsen-Kragh, J., Forre, O. and Natvig, J. B. 1993. Rheumatoid inflammatory T-cell clones express mostly Th1 but also Th2 and mixed (Th0-like) cytokine patterns. Scand. J. Immunol. 38:75.
6. Dolhain, R. J., van der Heiden, A. N., ter Haar, N. T., Breedveld, F. C. and Miltenburg, A. N. 1961. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum 39.
7. Courtenay, J. S., Dallman, M. J., Dayan, A. D., Martin, A. and Mosedale, B. 1980. Immunisation against heterologous type II collagen induces arthritis in mice. Nature 283:666.
8. Cho, Y. G., Cho, M. L., Min, S. Y. and Kim, H. Y. 2007. Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun. Rev. 7:65.
9. Khachigian, L. M. 2006. Collagen antibody-induced arthritis. Nat. Protoc. 1:25.
10. Velazquez, L., Fellous, M., Stark, G. R. and Pellegrini, S. 1992. A protein tyrosine kinase in the interferon α/β signaling pathway. Cell 70:313.
11. Stahl, N., Boulton, T. G., Farruggella, T. et al. 1994. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6b receptor components. Science 263:92.
12. Finbloom, D. S. and Winestock, K. D. 1995. IL-10 induces the tyrosine phosphorylation of Tyk2 and Jak1 and the differential assembly of Stat1 and Stat3 complexes in human T cells and monocytes. J. Immunol. 155:1079.
13. Bacon, C. M., McVicar, D. W., Ortaldo, J. R., Rees, R. C., O'Shea, J. J. and Johnston, J. A. 1995. Interleukin 12 (IL-12) induces tyrosine phosphorylation of Jak2 and Tyk2: differential use of Janus family kinases by IL-2 and IL-12. J. Exp. Med. 181:399.
14. Welham, M. J., Learmonth, L., Bone, H. and Schrader, J. W. 1995. Interleukin-13 signal transduction in lymphohemopoietic cells: similarities and differences in signal transduction with interleukin-4 and insulin. J. Biol. Chem. 270:12286.
15. Parham, C., Chirica, M., Timans, J. et al. 2002. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rß1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168:5699.
16. Shimoda, K., Kato, K., Aoki, K. et al. 2000. Tyk2 plays a restricted role in IFN-a signaling, although it is required for IL-12-mediated T cell function. Immunity 13:561.
17. Karaghiosoff, M., Neubauer, H., Lassnig, C. et al. 000. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13:549.
18. Shimoda, K., Kamesaki, K., Numata, A. et al. 2002. Cutting edge: tyk2 is required for the induction and nuclear translocation of Daxx which regulates IFN-alpha-induced suppression of B lymphocyte formation. J. Immunol. 169:4707.
19. Aoki, K., Shimoda, K., Oritani, K. et al. 2003. Limitin, an interferonlike cytokine, transduces inhibitory signals on B-cell growth through activation of Tyk2, but not Stat1, followed by induction and nuclear translocation of Daxx. Exp. Hematol. 31:1317.
20. Shimoda, K., Tsutsui, H., Aoki, K. et al. 2003. Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in Tyk2-deficient mice. Blood 99:2094.
21. Zamvil, S. S. and Steinman, L. 1990. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 8: 579.
22. Oyamada, A., Ikebe, H., Itsumi, M. et al. 2009. Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis. J. Immunol. 183:7539.
23. Shaw, M. H., Boyartchuk, V., Wong, S. et al. 2003. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc. Natl. Acad. Sci. USA. 100:11594.
24. Spach, K. M., Noubade, R., McElvany, B., Hickey, W. F., Blankenhorn, E. P. and Teuscher, C. 2009. A single nucleotide polymorphism in Tyk2 controls susceptibility to experimental allergic encephalomyelitis. J. Immunol. 182:7776.
25. Ortmann, R., Smeltz, R., Yap, G., Sher, A. and Shevach, E. M. 2001. A heritable defect in IL-12 signaling in B10.Q/J mice. I. In vitro analysis. J. Immunol. 166:5712.
26. Yap, G. S., Ortmann, R., Shevach, E. and Sher, A. 2001. A heritable defect in IL-12 signaling in B10.Q/J mice. I. I. Effect on acute resistance to Toxoplasma gondii and rescue by IL-18 treatment. J. Immunol. 166:5720.
27. Seto, Y., Nakajima, H., Suto, A. et al. 2003. Enhanced Th2 cellmediated allergic inflammation in Tyk2-deficient mice. J. Immunol. 170:1077.
28. Terato, K., Harper, D. S., Griffiths, M. M. et al. 1995. Collageninduced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity 22:137.
29. Muromoto, R., Ishida, M., Sugiyama, K. et al. 2006. Sumoylation of Daxx regulates IFN-induced growth suppression of B lymphocytes and the hormone receptor-mediated transactivation. J. Immunol. 177:1160.
30. Minegishi, Y., Saito, M., Morio, T. et al. 2006. Human tyrosine kinase deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25:745.
31. Korn, T., Bettelli, E., Oukka, M. and Kuchroo, V. K. 2009. IL-17 and Th17 cells. Annu. Rev. Immunol. 27:485.
32. Iwakura, Y. and Ishigame, H. 2006. The IL-23/IL-17 axis in inflammation. J. Clin. Invest. 116:1218.
33. Paniagua, R. T., Chang, A., Mariano, M. M. et al. 2010. c-Fmsmediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis. Arthritis Res. Ther. 12:R32.
34. Chia, W. T., Chen, Y. W., Cheng, L. Y., Lee, H. S., Chang, D. M. and Sytwu, H. K. 2008. MMP-9 mRNA as a therapeutic marker in acute and chronic stages of arthritis induced by type II collagen antibody. J. Formos. Med. Assoc. 107:245.
35. Itoh, T., Matsuda, H., Tanioka, M., Kuwabara, K., Itohara, S. and Suzuki, R. 2002. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J. Immunol. 169:2643.
36. Karaghiosoff, M., Steinborn, R., Kovarik, P. et al. 003. Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat. Immunol. 4:471.
37. Tokumasa, N., Suto, A., Kagami, S. et al. 2007. Expression of Tyk2 in dendritic cells is required for IL-12, IL-23, and IFN-c production and the induction of Th1 cell differentiation. Blood 110:553.
38. Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D. et al. 1999. A trial of etanercept, a recombinant tumor necrosis factor receptor: fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340:253.
39. Edwards, J. C., Szczepanski, L., Szechinski, J. et al. 2004. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350:2572.
40. Genovese, M. C., Becker, J. C., Schiff, M. et al. 2005. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353:1114.